Literature DB >> 27372708

Evaluation of diffusion-weighted imaging (DWI) and MR spectroscopy (MRS) as early response biomarkers in cervical cancer patients.

Stefania Rizzo1, Valentina Buscarino2, Daniela Origgi3, Paul Summers4, Sara Raimondi5, Roberta Lazzari6, Fabio Landoni7, Massimo Bellomi4,8.   

Abstract

PURPOSE: To prospectively assess whether choline levels and Apparent Diffusion Coefficient (ADC) values within cervical cancers before, during, and after non-surgical therapy are predictive of tumour response. PATIENTS AND METHODS: Patients undergoing MR examination for staging of cervical cancer, candidate for non-surgical therapy, were prospectively enrolled. According to the status at the end of therapies, patients were divided into responders and non-responders. The final outcome after a 5-year follow-up was classified as No Evidence of Disease (NED) or Progression of Disease (PD). Baseline values of mean ADC and Cho/H2O were compared between responders and non-responders, as well as between patients with NED and PD. The percent variation of ADC and Cho/H2O values over time was compared. P values <0.05 were considered significant.
RESULTS: 16 patients were included. There was no significant difference at baseline between responders (n = 12) and non-responders (n = 4), nor between NED (n = 11) PD patients (n = 5), in ADC values and Cho/H2O ratio. There was no significant difference in percent variation of ADC values and of Cho/H2O, comparing responders and non-responders. There was a significant increase in absolute values of ADC from the initial to mid-therapy MRI (p = 0.0001), while Cho/H2O was stable (p value: 0.61). In the four non-responders, the ADC increase was not significant (p value: 0.25), while it was significant in the 11 responders (p value: 0.001). Values of spectroscopy were stable in both responders and non-responders.
CONCLUSIONS: High increases of ADC values from baseline to mid-therapy MR reflect response to therapies. There were no significant variations in choline/water ratios over time.

Entities:  

Keywords:  Cervical cancer; DWI; MR spectroscopy; Response biomarkers

Mesh:

Substances:

Year:  2016        PMID: 27372708     DOI: 10.1007/s11547-016-0665-y

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  33 in total

1.  Role of conventional and diffusion weighted MRI in predicting treatment response after low dose radiation and chemotherapy in locally advanced carcinoma cervix.

Authors:  Saikat Das; Anuradha Chandramohan; Jeba Karunya Rami Reddy; Sramana Mukhopadhyay; Ramani Manoj Kumar; Rajesh Isiah; Subhashini John; Regi Oommen; Visalakshi Jeyaseelan
Journal:  Radiother Oncol       Date:  2015-10-20       Impact factor: 6.280

2.  In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization.

Authors:  Bin Wu; Wei-Jun Peng; Pei-Jun Wang; Ya-Jia Gu; Wen-Tao Li; Liang-Pin Zhou; Feng Tang; Guo-Ming Zhong
Journal:  Chin Med Sci J       Date:  2006-12

3.  In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS.

Authors:  Ming Q Huang; David S Nelson; Stephen Pickup; Hui Qiao; E James Delikatny; Harish Poptani; Jerry D Glickson
Journal:  Acad Radiol       Date:  2007-12       Impact factor: 3.173

4.  Reproducibility of total choline/water ratios in mouse U87MG xenograft tumors by 1H-MRS.

Authors:  Mingming Zhu; Anthony S Fischl; Melissa A Trowbridge; Harlan E Shannon
Journal:  J Magn Reson Imaging       Date:  2012-04-19       Impact factor: 4.813

5.  Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization.

Authors:  Jie Deng; Frank H Miller; Thomas K Rhee; Kent T Sato; Mary F Mulcahy; Laura M Kulik; Riad Salem; Reed A Omary; Andrew C Larson
Journal:  J Vasc Interv Radiol       Date:  2006-07       Impact factor: 3.464

6.  Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T.

Authors:  Sina Meisamy; Patrick J Bolan; Eva H Baker; Robin L Bliss; Evin Gulbahce; Lenore I Everson; Michael T Nelson; Tim H Emory; Todd M Tuttle; Douglas Yee; Michael Garwood
Journal:  Radiology       Date:  2004-11       Impact factor: 11.105

7.  (1)H magnetic resonance spectroscopy of preinvasive and invasive cervical cancer: in vivo-ex vivo profiles and effect of tumor load.

Authors:  Marrita M Mahon; I Jane Cox; Roberto Dina; W Patrick Soutter; G Angus McIndoe; Andreanna D Williams; Nandita M deSouza
Journal:  J Magn Reson Imaging       Date:  2004-03       Impact factor: 4.813

8.  Diffusion-weighted MRI in cervical cancer.

Authors:  Patrick Z McVeigh; Aejaz M Syed; Michael Milosevic; Anthony Fyles; Masoom A Haider
Journal:  Eur Radiol       Date:  2008-01-12       Impact factor: 5.315

9.  Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer.

Authors:  Vanessa N Harry; Scott I Semple; Fiona J Gilbert; David E Parkin
Journal:  Gynecol Oncol       Date:  2008-09-06       Impact factor: 5.482

10.  Pre-treatment diffusion-weighted MR imaging for predicting tumor recurrence in uterine cervical cancer treated with concurrent chemoradiation: value of histogram analysis of apparent diffusion coefficients.

Authors:  Suk Hee Heo; Sang Soo Shin; Jin Woong Kim; Hyo Soon Lim; Yong Yeon Jeong; Woo Dae Kang; Seok Mo Kim; Heoung Keun Kang
Journal:  Korean J Radiol       Date:  2013-07-17       Impact factor: 3.500

View more
  6 in total

1.  Staging, recurrence and follow-up of uterine cervical cancer using MRI: Updated Guidelines of the European Society of Urogenital Radiology after revised FIGO staging 2018.

Authors:  Lucia Manganaro; Yulia Lakhman; Nishat Bharwani; Benedetta Gui; Silvia Gigli; Valeria Vinci; Stefania Rizzo; Aki Kido; Teresa Margarida Cunha; Evis Sala; Andrea Rockall; Rosemarie Forstner; Stephanie Nougaret
Journal:  Eur Radiol       Date:  2021-04-14       Impact factor: 5.315

2.  Do DWI and quantitative DCE perfusion MR have a prognostic value in high-grade serous ovarian cancer?

Authors:  Francesca De Piano; Valentina Buscarino; Dulia Maresca; Patrick Maisonneuve; Giovanni Aletti; Roberta Lazzari; Andrea Vavassori; Massimo Bellomi; Stefania Rizzo
Journal:  Radiol Med       Date:  2019-08-31       Impact factor: 3.469

3.  Imaging Biomarkers and Liquid Biopsy in Assessment of Cervical Cancer.

Authors:  Mansur A Ghani; Joy Liau; Ramez Eskander; Loren Mell; Tahir Yusufaly; Sebastian Obrzut
Journal:  J Comput Assist Tomogr       Date:  2022-08-16       Impact factor: 2.081

Review 4.  The value of advanced MRI techniques in the assessment of cervical cancer: a review.

Authors:  Evelyn Dappa; Tania Elger; Annette Hasenburg; Christoph Düber; Marco J Battista; Andreas M Hötker
Journal:  Insights Imaging       Date:  2017-08-21

Review 5.  Quantitative Magnetic Resonance Imaging for Biological Image-Guided Adaptive Radiotherapy.

Authors:  Petra J van Houdt; Yingli Yang; Uulke A van der Heide
Journal:  Front Oncol       Date:  2021-01-29       Impact factor: 6.244

6.  The contribution of the 1H-MRS lipid signal to cervical cancer prognosis: a preliminary study.

Authors:  Miriam Dolciami; Rossella Canese; Claudia Testa; Angelina Pernazza; Giusi Santangelo; Innocenza Palaia; Carlo Della Rocca; Carlo Catalano; Lucia Manganaro
Journal:  Eur Radiol Exp       Date:  2022-10-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.